The Public Health Value of Opioid Litigation
The Public Health Value of Opioid Litigation
复制标题
DOI：
10.1177/1073110520935340
复制
发表时间：
2020-06-01
影响因子：
2.1
通讯作者：
Haffajee, Rebecca L.
中科院分区：
文献类型：
--
作者：
Haffajee, Rebecca L.
阿片类药物诉讼延续了日益增长的公共卫生诉讼趋势，政府寻求让公司对其产品相关的人口危害负责。诉讼可有助于解决监管和立法决策以及处方类阿片领域普遍存在的市场自我监管方面的差距。此外，之前的阿片类药物和解已经满足了民事侵权诉讼的目标，即为受害方获得赔偿，阻止有害行为，并让某些阿片类药物制造商、分销商和药房对其行为负责。通过这种方式，阿片类药物诉讼代表了先前涉及烟草，含铅油漆和石棉的公共卫生诉讼活动的进步，这些诉讼活动的侵权诉讼影响更为有限。虽然阿片类药物诉讼不是阿片类药物危机的全面解决方案，但它可以补充其他策略，并为处方阿片类药物和相关危害注入急需的资金，行为改变和公共责任。
Opioid litigation continues a growing public health litigation trend in which governments seek to hold companies responsible for population harms related to their products. The litigation can serve to address gaps in regulatory and legislative policymaking and in market self-regulation pervasive in the prescription opioid domain. Moreover, prior opioid settlements have satisfied civil tort litigation objectives of obtaining compensation for injured parties, deterring harmful behavior, and holding certain opioid manufacturers, distributors and pharmacies accountable for their actions. In this way, opioid litigation represents progress over prior public health litigation campaigns involving tobacco, lead paint, and asbestos, which had more limited tort litigation effects. Although opioid litigation is not a comprehensive solution to the opioid crisis, it can complement other strategies and infuse much needed money, behavior changes, and public accountability for prescription opioid and related harms.